Drug intelligence / Profile preview

azathioprine + isotretinoin + methylprednisolone

Development stage
Unknown
Lead developer
GSK
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral, Intravenous, Intramuscular, Topical
01

Overview

This is a combination of three pharmaceutical agents—azathioprine, isotretinoin, and methylprednisolone. - **Azathioprine** is an immunosuppressant prodrug of 6-mercaptopurine, primarily used to prevent organ transplant rejection and treat autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. It works by inhibiting purine synthesis required for DNA replication in immune cells, thereby suppressing the immune response[3][6]. - **Isotretinoin** is a retinoid derivative of vitamin A used mainly for severe acne that has not responded to other treatments. It reduces sebaceous gland size and sebum production, inhibits comedogenesis, decreases inflammation, and normalizes keratinization[8]. - **Methylprednisolone** is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties. It modulates gene expression to decrease the production of inflammatory mediators and suppresses various components of the immune system[7][10]. There are no known fixed-dose or branded pharmaceutical products containing all three agents together; however, combinations involving two (e.g., azathioprine plus corticosteroids or isotretinoin plus corticosteroids) are sometimes used in clinical practice for specific indications such as severe inflammatory conditions or refractory autoimmune diseases[6][9]. The triple combination would be highly unusual due to overlapping immunosuppressive effects and increased risk of adverse events.

02

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on azathioprine + isotretinoin + methylprednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on azathioprine + isotretinoin + methylprednisolone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call